Page 2
Page 2
Axon growth and guidance
The complexarchitectureofneuronal networks togetherwith the extraordinary associated functions make the nervous system a fascinating biological structure. The considerable work performed to explore this cellular machinery is nowadays successfulbecause the mysteryofnervous system developmentisbeing unravelled. As described in their outstanding review published 10 years ago in Science.' Marc Tessier-Lavigne and Corey Goodman-the pioneers of the molecular era of axon guidance-summarized the assembly of nervous system connections as a subtle game of attraction and repulsion of neuronal growth cones. The cellular ballet ensuring the formation of billions of synapses, which ultimately gives rise to the highest cognitive functions, is primarily orchestrated by a step-by-step mechanism of growth driven by multiple molecular cues. While our general concept of axon guidance remains identical, a profound evolution ofour knowledge ofthe molecular identityofthe guidance cues together with their interactions and signalling pathways occurred over the past ten years.
Antifouling Compounds
Increasing awareness of the deleterious effects of toxic components in antifouling coatings has raised interest in the potential for nontoxic alternatives. This book examines how marine organisms from bacteria to invertebrates and plants use chemicals to communicate and defend themselves. Chemicals that prevent colonisation of living surfaces are particularly pertinent to antifouling technology and may inspire new solutions. The challenge is to identify such compounds, identify the means for sustainable production and incorporate them into coatings to give long-term antifouling efficacy.
Advances in Targeted Cancer Therapy
This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed.
